Accelerator Parallel Analyses: Developing key research questions that multiple organizations and teams can address simultaneously.
In the Diagnostics Parallel Analysis effort, collaborators are deploying the parallel analysis approach with an initial focus on illustrating COVID-19 testing practices as well as test performance. The Diagnostics Accelerators are first exploring (and connecting) the various data elements necessary for RWD efforts with hundreds of available tests, and then exploring the connection between positive RNA and serology tests.
The primary research aim is to address test characteristics that reside in a data ecosystem and use that information to address the connection between positive RNA and serology tests.
There are 4 research components that the Work Group will be addressing: (1) Describe RNA tested by demographic, behavioral and environmental characteristics, baseline clinical presentation, key comorbidities, and bacterial/viral co-infections; (2) Describe serological testing by demographic, behavioral and environmental characteristics, baseline clinical presentation, key comorbidities, and bacterial/viral co-infections; (3) Characterize the timing of serology testing relative to symptom onset or RNA date by demographic, behavioral and environmental characteristics, baseline clinical presentation, key comorbidities, bacterial/viral co-infections, and test characteristics (e.g. manufacturer); and (4)Describe demographic, behavioral and environmental characteristics, baseline clinical presentation, key comorbidities, bacterial/viral co-infections, and test characteristics (e.g. manufacturer) associated with positive serology (+Ab) vs. negative serology (-AB).
Repeating analyses in parallel through collaborators using different analytical techniques and data sources helps strengthen findings and learnings. Additionally, this effort will help validate the role of real-world data as a tool for rapidly learning about patient, environment, and test characteristics in a data ecosystem (Electronic Health Record, Laboratory Information System, and Instrument), and outcomes associated with positive RNA test and serology tests for COVID-19.
